NAN -33.41%: the disinfectant device company fell to 5-year lows today after they flagged slow sales after market yesterday. Their TROPHON product, used on ultrasound transfusers, has seen upgrades in the first half down 22.5% on 1HFY23, and new installed units dropped 13.4%. The company has blamed tighter budgets in hospitals and longer sales cycles pushing out deals into the second half for the soft performance. They’re continuing to work on bringing its new CORIS product, used on endoscopes, to market, a much-delayed process that is still awaiting FDA approval. While the product is a market leader, Nanosonics is facing some headwinds market-wise and of their own creation.
scroll
Gerrish: The correction is done, we’re positioning for what comes next
Close
A discussion with Geoff Wilson – Wilson Asset Management & James Gerrish – Market Matters
Close
Friday 9th May – Dow up +254pts, SPI up +3pts
Close
MM is neutral/negative NAN, though it will look more interesting ~$2.50
Add To Hit List
Relevant suggested news and content from the site

Video
WATCH
Gerrish: The correction is done, we’re positioning for what comes next
The Market Matters lead portfolio manager talks the recent recovery, Trump, gold, and why he thinks there's plenty of opportunities.

Video
WATCH
A discussion with Geoff Wilson – Wilson Asset Management & James Gerrish – Market Matters
Recorded Monday 31st March

Podcast
LISTEN
Friday 9th May – Dow up +254pts, SPI up +3pts
Daily Podcast Direct from the Desk
Members only
UNLOCK MARKET MATTERS NOW
Take a free trial.
No payment details required.